Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first-generation antibody therapies in terms of potency, stability, effect duration, and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech. We are establishing a proprietary pipeline of differentiated therapeutics by targeting clinically validated pathways with multispecific molecules to create novel mechanisms of action designed to differentiate from standard of care by superior efficacy and favorable safety. Our most advanced program, ND021, exemplifies this strategy by blocking immune-suppressive PD-(L)1 signaling with best-in-class potency and simultaneously triggering 4-1BB-mediated T cell stimulation specifically in the tumor microenvironment. ND021 is currently being evaluated in a Phase 1/2 clinical study.
This company is:
View all products
Keywords
Industries
Where is Numab located?
The company Numab is located in Wädenswil, Zurich, Switzerland. It's worth noting that the company may has more corporate locations
How many employees does Numab approximately have?
As of the latest available information Numab has around 11-50 employees worldwide.
When was Numab founded?
Numab was founded in 2011
In which industries does Numab mainly work?
The company Numab has it's main focus in the industries of Biotechnology, Health Care, Science and Engineering, Manufacturing
Elpis Biopharmaceuticals
United States
11-50 Employees
2017
KisoJi Biotechnology
Canada
1-10 Employees
2009
RubrYc Therapeutics
United States
11-50 Employees
2017
BUGWORKS Research
India
11-50 Employees
2014
Tikcro
Israel
1-10 Employees
1999
NMS Group
Italy
251-500 Employees
2012
Ab Studio
United States
11-50 Employees
2017
Scorpion Therapeutics
United States
11-50 Employees
2020
Topics which have been searched by others and may be interesting for you: